Mycophenolate Mofetil

• UNSPSC Description:

  Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation[1].

• Target Antigen:

  Apoptosis; Bacterial; Drug Metabolite; Endogenous Metabolite

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mycophenolate-mofetil.html

• Purity:

  99.91

• Solubility:

  1M NaOH : 33.33 mg/mL (ultrasonic;adjust pH to 12 with 1M NaOH)|DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(OCCN1CCOCC1)CC/C(C)=C/CC2=C(O)C3=C(COC3=O)C(C)=C2OC

• Molecular Weight:

  433.49

• References & Citations:

  [1]Simmons WD, et al. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17(2):75-92.|[2]Fulton B, et al. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51(2):278-298.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  128794-94-5